Found 28 of ph data with Target = 'Broad substrate specificity ATP-binding cassette transporter ABCG2'
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: 600nMpH: 7.4 T: 2°CAssay Description:To determine potency of compounds on inhibition of transporters, bi-directional transport studies are performed in Caco-2 cells (American Type Cultur...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: 790nMpH: 7.4 T: 2°CAssay Description:IC50 and maximal activities for inhibition of PhA accumulation were determined from dose-response curves. The accumulation of PhA, a fluorescent ABCG...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: 1.98E+3nMpH: 7.4 T: 2°CAssay Description:To determine potency of compounds on inhibition of transporters, bi-directional transport studies are performed in Caco-2 cells (American Type Cultur...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: 2.60E+3nMpH: 7.4 T: 2°CAssay Description:IC50 and maximal activities for inhibition of PhA accumulation were determined from dose-response curves. The accumulation of PhA, a fluorescent ABCG...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: 3.25E+3nMpH: 7.4 T: 2°CAssay Description:To determine potency of compounds on inhibition of transporters, bi-directional transport studies are performed in Caco-2 cells (American Type Cultur...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: 3.70E+3nMpH: 7.4 T: 2°CAssay Description:IC50 and maximal activities for inhibition of PhA accumulation were determined from dose-response curves. The accumulation of PhA, a fluorescent ABCG...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: 3.90E+3nMpH: 7.4 T: 2°CAssay Description:IC50 and maximal activities for inhibition of PhA accumulation were determined from dose-response curves. The accumulation of PhA, a fluorescent ABCG...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: 4.30E+3nMpH: 7.4 T: 2°CAssay Description:IC50 and maximal activities for inhibition of PhA accumulation were determined from dose-response curves. The accumulation of PhA, a fluorescent ABCG...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: 4.50E+3nMpH: 7.4 T: 2°CAssay Description:IC50 and maximal activities for inhibition of PhA accumulation were determined from dose-response curves. The accumulation of PhA, a fluorescent ABCG...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: 4.60E+3nMpH: 7.4 T: 2°CAssay Description:IC50 and maximal activities for inhibition of PhA accumulation were determined from dose-response curves. The accumulation of PhA, a fluorescent ABCG...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: 5.40E+3nMpH: 7.4 T: 2°CAssay Description:IC50 and maximal activities for inhibition of PhA accumulation were determined from dose-response curves. The accumulation of PhA, a fluorescent ABCG...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: 5.80E+3nMpH: 7.4 T: 2°CAssay Description:IC50 and maximal activities for inhibition of PhA accumulation were determined from dose-response curves. The accumulation of PhA, a fluorescent ABCG...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: 6.90E+3nMpH: 7.4 T: 2°CAssay Description:IC50 and maximal activities for inhibition of PhA accumulation were determined from dose-response curves. The accumulation of PhA, a fluorescent ABCG...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: 9.70E+3nMpH: 7.4 T: 2°CAssay Description:IC50 and maximal activities for inhibition of PhA accumulation were determined from dose-response curves. The accumulation of PhA, a fluorescent ABCG...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: >1.00E+4nMpH: 7.4 T: 2°CAssay Description:To determine potency of compounds on inhibition of transporters, bi-directional transport studies are performed in Caco-2 cells (American Type Cultur...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: >1.00E+4nMpH: 7.4 T: 2°CAssay Description:To determine potency of compounds on inhibition of transporters, bi-directional transport studies are performed in Caco-2 cells (American Type Cultur...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: >1.00E+4nMpH: 7.4 T: 2°CAssay Description:To determine potency of compounds on inhibition of transporters, bi-directional transport studies are performed in Caco-2 cells (American Type Cultur...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: >1.00E+4nMpH: 7.4 T: 2°CAssay Description:To determine potency of compounds on inhibition of transporters, bi-directional transport studies are performed in Caco-2 cells (American Type Cultur...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: 1.12E+4nMpH: 7.4 T: 2°CAssay Description:IC50 and maximal activities for inhibition of PhA accumulation were determined from dose-response curves. The accumulation of PhA, a fluorescent ABCG...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: 1.18E+4nMpH: 7.4 T: 2°CAssay Description:IC50 and maximal activities for inhibition of PhA accumulation were determined from dose-response curves. The accumulation of PhA, a fluorescent ABCG...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: 1.64E+4nMpH: 7.4 T: 2°CAssay Description:IC50 and maximal activities for inhibition of PhA accumulation were determined from dose-response curves. The accumulation of PhA, a fluorescent ABCG...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: 1.67E+4nMpH: 7.4 T: 2°CAssay Description:IC50 and maximal activities for inhibition of PhA accumulation were determined from dose-response curves. The accumulation of PhA, a fluorescent ABCG...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: 2.33E+4nMpH: 7.4 T: 2°CAssay Description:IC50 and maximal activities for inhibition of PhA accumulation were determined from dose-response curves. The accumulation of PhA, a fluorescent ABCG...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: 2.69E+4nMpH: 7.4 T: 2°CAssay Description:IC50 and maximal activities for inhibition of PhA accumulation were determined from dose-response curves. The accumulation of PhA, a fluorescent ABCG...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: 3.34E+4nMpH: 7.4 T: 2°CAssay Description:IC50 and maximal activities for inhibition of PhA accumulation were determined from dose-response curves. The accumulation of PhA, a fluorescent ABCG...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: 4.14E+4nMpH: 7.4 T: 2°CAssay Description:IC50 and maximal activities for inhibition of PhA accumulation were determined from dose-response curves. The accumulation of PhA, a fluorescent ABCG...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DatapH: 7.4 T: 2°CAssay Description:IC50 and maximal activities for inhibition of PhA accumulation were determined from dose-response curves. The accumulation of PhA, a fluorescent ABCG...More data for this Ligand-Target Pair
TargetBroad substrate specificity ATP-binding cassette transporter ABCG2(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DatapH: 7.4 T: 2°CAssay Description:IC50 and maximal activities for inhibition of PhA accumulation were determined from dose-response curves. The accumulation of PhA, a fluorescent ABCG...More data for this Ligand-Target Pair